Literature DB >> 2182067

Endogenous substances as drugs. Issues related to the application of cytokines in cancer therapy.

D R Parkinson1.   

Abstract

Cytokines are the protein products of cells which regulate proliferation, differentiation and functional activation. The potent biological properties of these proteins have led to their introduction into clinical medicine as pharmacological agents. The cytokines most studied to date include the interferons, some of the interleukins and the haematopoietic growth factors. Although they have most often been studied in cancer patients, widespread application of these agents in many other fields is likely. Despite the fact that these are recombinant proteins of defined sequence, their intricate biology complicates clinical investigation. Proteins may be of native or mutated sequence and their degree of glycosylation is further affected by the expression system used for their production. Furthermore, although these cytokines interact with specific cell surface receptors, pleotropic biological consequences may follow from the interaction of ligand with receptors. As a consequence, significant dose and schedule dependency exists for these agents, and the particular administration regimen as well as the route of delivery may greatly affect the biological and clinical characteristics of these drugs. Thus, direct comparisons of different cytokine problems may be difficult. These issues reinforce the need for increased biological understanding of cytokines if these agents are to be used rationally and safely in clinical medicine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2182067     DOI: 10.2165/00002018-199000051-00012

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  17 in total

Review 1.  Additional indications for interferon therapy: basal cell carcinoma, carcinoid, and chronic active hepatitis.

Authors:  R J Spiegel
Journal:  Semin Oncol       Date:  1988-10       Impact factor: 4.929

Review 2.  Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.

Authors:  S A Rosenberg
Journal:  Important Adv Oncol       Date:  1986

3.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

Review 4.  Lessons from the clinical trials of interleukin-2.

Authors:  D R Parkinson
Journal:  Nat Immun Cell Growth Regul       Date:  1990

5.  Administration of slowly released recombinant interleukin 2. Augmentation of the efficacy of adoptive immunotherapy with lymphokine-activated killer (LAK) cells.

Authors:  T Nishimura; Y Uchiyama; H Yagi; Y Hashimoto
Journal:  J Immunol Methods       Date:  1986-07-11       Impact factor: 2.303

6.  Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.

Authors:  J A Thompson; D J Lee; C G Lindgren; L A Benz; C Collins; D Levitt; A Fefer
Journal:  J Clin Oncol       Date:  1988-04       Impact factor: 44.544

7.  Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.

Authors:  M B Atkins; J W Mier; D R Parkinson; J A Gould; E M Berkman; M M Kaplan
Journal:  N Engl J Med       Date:  1988-06-16       Impact factor: 91.245

8.  Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

Authors:  R I Fisher; C A Coltman; J H Doroshow; A A Rayner; M J Hawkins; J W Mier; P Wiernik; J D McMannis; G R Weiss; K A Margolin
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

9.  In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

Authors:  M T Lotze; Y L Matory; S E Ettinghausen; A A Rayner; S O Sharrow; C A Seipp; M C Custer; S A Rosenberg
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

10.  Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.

Authors:  D L Fraker; H N Langstein; J A Norton
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.